NF-κB p65 is therefore identified as an attractive target for development of anti-inflammatory therapies that would not further impair already deficient IFN responses in exacerbations of asthma and chronic obstructive pulmonary disorder (COPD). This evidence concerns the gene RELA and chronic obstructive pulmonary disease.